Roundtable On Coronavirus Pharma Industry Impact In China, Korea, - PowerPoint PPT Presentation

Roundtable On Coronavirus Pharma Industry Impact In China, Korea, And Japan Discussing experiences and lessons across East Asia

Speakers Panelists Moderator Brian Yang Ian Haydock Jung Won Shin Senior Editor, Editor-in-Chief, Pharma Senior Reporter, Insights, APAC Insights, APAC Insights, APAC Pharma Intelligence Pharma Intelligence Pharma Intelligence (China) (Tokyo) (Seoul) informa | Pharma Intelligence 2

Agenda Region-Specific Insights into: • Current Local Situation • Industry Response & Impact • R&D Activity • Policy & Regulatory Approaches & Lessons Common Themes? Q&A Informa Pharma Intelligence 3

China and COVID-19: Treatments, Vaccines and Lessons Learned Brian Yang Brian.Yang@informa.com

China Emerges Early from COVID Wuhan lockdown on Beijing remained in Fast approval of viral Second wave fear, social Jan.23 - drastic measures lockdown until early May testing kits and antiviral tracing, massive testing spread to Beijing and and other drugs and fast vaccine most of the country development Photos: Brian Yang informa | Pharma Intelligence 5

China: Antiviral trials • Early start for several leading antivirals • Local trials for Gilead’s remdesivir • Others: hydroxychloroquine, Avigan (favipiravir)

Leading Vaccines Race • Out of 16 vaccines currently in clinical studies globally, five are from China • CanSino, state-owned Sinopharm leading the pack with Phase III trials • Year-end approval likely and “public good” as promised by authorities

China: Lessons Learned • Less prepared even after SARS outbreak in 2003 • Quick approval of testing kits allowed early and mass testing • Slow easing of lockdowns restrictions, 100% mask-wearing and social tracing • Combination with traditional medicines in treating COVID patients

Questions Remain • China has not authorized antivirals for COVID, instead relying on traditional medicines • Most vaccines based on inactivated virus, an old technology • New drugs in pipeline: antibodies among others

Thank You Brian Yang Brian.Yang@informa.com 10

Japan and COVID-19 Ian Haydock Ian.Haydock@informa.com

Relatively Low Case Numbers • Attributed to high compliance with voluntary lock-down (social responsibility) • Familiarity with mask-wearing in public • Targeted testing/tracing of clusters

Industry Impact • Still early – some trial recruitment affected but impact unclear • Ongoing need for chronic drugs for serious diseases • Uptake of new tools? Remote rep ‘visits’, online Dr education, smaller salesforce?

R&D Activity • Antivirals – Avigan (late July data?) Trial recruitment issues • Plasma/antibody therapies – Takeda, Chugai • Vaccines – Shionogi/UMN (rDNA) and AnGes (DNA): H1/Q3 ‘21? • New ‘Fugaku’ supercomputer screening for drugs

Regulatory Approaches • Rapid emergency approval of Dx and Gilead’s remdesivir (just days) • Clear guidance on fast-track system and regulatory responsibilities • PMDA sees provision of pandemic solutions as top priority

South Korea and COVID-19 Jung Won Shin Jungwon.Shin@informa.com

South Korea • Overview • Policy & Regulatory • Pharma R&D Activity

Common Themes? Respond To Unique Value Of Supportive Local Situation Regulators Regional Collaboration Leverage National On Antibodies, Expertise Antivirals Be Fast, Be Flexible Product name goes here – i.e. Citeline 18

Q&A informa | Pharma Intelligence 19

Thank You!